Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
This is a randomized placebo controlled study to test whether a single 14 course of treatment
with the anti-CD3 monoclonal antibody, hOKT3gamma1(Ala-Ala),Teplizumab will prevent the loss
of insulin secretory capacity in individuals with Type 1 diabetes of 4 - 12 months duration
since diagnosis.
Phase:
Phase 2
Details
Lead Sponsor:
Yale University
Collaborators:
Juvenile Diabetes Research Foundation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)